ANSWER: B

Rationale:

The blood:gas partition coefficient directly determines the speed of inhalational anesthetic equilibration between alveolar gas, blood, and brain. A lower coefficient means less agent must dissolve in blood before alveolar partial pressure rises to anesthetic levels, producing faster induction; the same principle applies in reverse at emergence, when rapid fall in alveolar concentration drives rapid offset. Desflurane has a blood:gas partition coefficient of approximately 0.42, the lowest of any halogenated volatile agent in clinical use, and this property makes it the agent producing the fastest emergence — a clinically important advantage in procedures requiring rapid postoperative neurological assessment such as neurosurgery, bariatric surgery, and prolonged ambulatory cases. Option A: Isoflurane's blood:gas coefficient of approximately 1.4 places it in an intermediate range; it provides faster emergence than halothane or enflurane but is considerably slower than desflurane or sevoflurane, making it incorrect as the fastest agent. Option B: Correct. Desflurane's blood:gas coefficient of 0.42 is the lowest among halogenated agents, accounting for its uniquely rapid emergence. Option C: Sevoflurane's coefficient of approximately 0.65 is the second lowest among halogenated agents and provides fast emergence suitable for ambulatory surgery, but desflurane remains faster, making this option incorrect as the fastest. Option D: Halothane's coefficient of approximately 2.4 is the highest of the commonly used volatile agents, producing the slowest induction and emergence — the opposite of what the question asks. Option E: Enflurane's coefficient of approximately 1.9 reflects high blood solubility similar to halothane, producing slow equilibration and slow emergence, making it incorrect.

ANSWER: E

Rationale:

Halothane uniquely sensitizes the myocardium to catecholamine-induced arrhythmias through mechanisms involving altered calcium handling and membrane stabilization changes in ventricular myocytes. This sensitization is clinically significant: ventricular arrhythmias including ventricular tachycardia can be provoked by epinephrine doses as low as 1.5 to 2 mcg/kg when infiltrated during halothane anesthesia — a threshold far below that seen with isoflurane, sevoflurane, or desflurane. This property is a major clinical disadvantage of halothane and requires limiting the dose of epinephrine used with local anesthetics during halothane-based anesthesia, or avoiding epinephrine-containing solutions altogether when feasible. Modern halogenated ethers do not share this catecholamine sensitization property to a clinically meaningful degree. Option A: Halothane and lidocaine are both metabolized by CYP2E1, but competitive inhibition at clinical concentrations does not produce clinically significant lidocaine toxicity. The primary concern with epinephrine is arrhythmia via myocardial sensitization, not lidocaine accumulation, making this option incorrect. Option B: Coronary steal is a theoretical concern associated with isoflurane, not halothane, and the mechanism involves coronary vasodilation diverting flow from collateral-dependent territories — a different pharmacological concern entirely unrelated to epinephrine co-administration with halothane. Option C: Halothane does not block beta-adrenergic receptors. It produces myocardial depression and bradycardia through direct effects on cardiomyocyte calcium handling, not through adrenergic receptor antagonism, making this mechanistically incorrect. Option D: Halothane produces dose-dependent uterine relaxation, but epinephrine does not reverse this effect in a clinically meaningful way. The premise of this option is pharmacologically unfounded and does not describe a recognized interaction. Option E: Correct. Halothane's catecholamine sensitization is the defining clinical concern when epinephrine is used during halothane anesthesia, with ventricular arrhythmias possible at doses as low as 1.5 to 2 mcg/kg of infiltrated epinephrine.

ANSWER: C

Rationale:

The minimum alveolar concentration (MAC) is defined as the alveolar concentration of an anesthetic agent at which 50% of patients do not move in response to a standard surgical stimulus (skin incision). For nitrous oxide, the MAC is approximately 104% in oxygen at atmospheric pressure, meaning that even breathing 100% nitrous oxide — which is the maximum physically achievable at 1 atmosphere — falls short of the concentration required to achieve surgical anesthesia in half of patients. This fundamental pharmacokinetic limitation means nitrous oxide can never function as a sole anesthetic agent at sea level or standard clinical pressures. It is always used as an adjunct to reduce the required concentration of volatile or intravenous agents (the MAC-sparing or anesthetic-sparing effect), exploiting its rapid kinetics and analgesic properties without attempting to achieve surgical anesthesia with it alone. In hyperbaric conditions, such as at 2 atmospheres of pressure, nitrous oxide can theoretically produce unconsciousness, but this is not clinically practical. Option A: Nitrous oxide actually has a very low blood:gas partition coefficient of approximately 0.47, making it one of the least blood-soluble inhalational agents and producing very rapid equilibration — the opposite of slow or unpredictable. This option describes the behavior of high-solubility agents such as halothane, making it incorrect. Option B: Nitrous oxide does possess significant analgesic properties, mediated through endogenous opioid mechanisms and N-methyl-D-aspartate (NMDA) receptor antagonism, at clinically used concentrations. Lack of analgesia is not the reason it cannot be used as a sole agent, making this option incorrect. Option C: Correct. The MAC of nitrous oxide exceeds 100% at atmospheric pressure, making surgical anesthesia impossible with this agent alone at sea level, regardless of the inspired concentration achievable. Option D: Nitrous oxide actually has a mild sympathomimetic cardiovascular effect, tending to maintain or slightly increase heart rate and blood pressure; it does not cause profound cardiovascular depression. This is one reason it is favored as an adjunct in patients with reduced cardiovascular reserve, making this option incorrect. Option E: Nitrous oxide is a gas at room temperature stored as a compressed liquid and is delivered directly from cylinders through flowmeters, not through precision vaporizers. However, this is a delivery method difference, not a reason it cannot achieve surgical anesthesia; the fundamental limitation is its MAC exceeding 100%, not the delivery apparatus, making this option incorrect.

ANSWER: A

Rationale:

Sevoflurane is the agent of choice for inhalational induction in pediatric patients, and its selection reflects a combination of favorable properties that no other currently available agent matches in this clinical context. Its blood:gas partition coefficient of approximately 0.65 is low enough to produce rapid onset — faster than halothane, isoflurane, or enflurane — while its non-pungent, somewhat sweet odor is well tolerated during mask induction, an essential feature when IV access is absent and the patient must breathe the anesthetic voluntarily. Sevoflurane is a bronchodilator and is hemodynamically stable at induction doses, making it suitable across a wide range of pediatric patients including those with reactive airways. These combined properties — rapid kinetics, airway acceptability, bronchodilation, and cardiovascular stability — make it the standard of care for pediatric inhalational induction in high-resource settings. Option A: Correct. Sevoflurane's combination of low blood solubility, non-pungent odor, bronchodilation, and hemodynamic stability makes it the agent of choice for pediatric inhalational induction. Option B: Desflurane is contraindicated for inhalational induction in any patient, pediatric or adult, because it is a significant airway irritant at induction concentrations, commonly provoking coughing, breath-holding, laryngospasm, and bronchospasm. Its use is restricted to maintenance after induction with an intravenous agent, making this option incorrect. Option C: Halothane was historically used for pediatric inhalational induction and remains in use in low-resource settings; however, its disadvantages — higher hepatotoxicity risk, significant myocardial depression, catecholamine sensitization, and the availability of sevoflurane — have made it a second-line agent where sevoflurane is available. This option would only be appropriate in a resource-limited context, not as the preferred agent generally. Option D: Isoflurane has a pungent odor that causes airway irritation and is poorly tolerated during inhalational induction in children, frequently producing breath-holding and laryngospasm. It is not suitable as an induction agent, making this option incorrect. Option E: Nitrous oxide cannot achieve surgical anesthesia as a sole agent because its MAC exceeds 100% at atmospheric pressure, as discussed previously. While it can be used as a premedicant or adjunct to reduce anxiety before sevoflurane introduction, it cannot substitute as the primary induction agent, making this option incorrect.

ANSWER: D

Rationale:

Desflurane's principal clinical limitation as an induction agent is its potent airway irritant property. At concentrations required for induction (greater than approximately 1 MAC, or 6–7% in oxygen), desflurane consistently provokes coughing, breath-holding, laryngospasm, increased secretions, and occasionally bronchospasm in awake or lightly sedated patients. This makes mask induction not merely unpleasant but unsafe: laryngospasm in a patient without IV access and without a secured airway is a potentially life-threatening complication. For this reason, desflurane is universally restricted to maintenance anesthesia, administered only after induction with an intravenous agent (typically propofol or thiopental) and after the airway has been secured. In the clinical scenario described — bariatric surgery requiring rapid emergence — the correct approach is IV induction followed by desflurane maintenance, not inhalational induction with desflurane. Option A: Desflurane MAC of 6 to 7% is achievable in a breathing circuit; the limitation is not the inspired concentration attainable but the airway irritation caused at induction doses. This option misidentifies the mechanism of the limitation, making it incorrect. Option B: While rapid changes in anesthetic depth are a real consideration with desflurane, this is managed by gradual concentration changes during maintenance, not by avoiding induction. The specific danger during induction is airway irritation, not excessive titration speed, making this option incorrect. Option C: Desflurane does require a heated, pressurized vaporizer, but this vaporizer can deliver desflurane to a face mask circuit; the technical delivery issue is not why induction is avoided. The reason is airway irritation at induction concentrations, making this option incorrect. Option D: Correct. Desflurane's airway irritant property at induction concentrations makes it unsafe for mask induction in any patient, producing laryngospasm and bronchospasm that create dangerous airway emergencies. Option E: Desflurane does not produce severe cardiovascular depression at induction concentrations; it can cause transient sympathetic activation (tachycardia and hypertension) on rapid concentration increases during maintenance, but cardiovascular depression is not the reason inhalational induction is avoided. This option incorrectly identifies the mechanism, making it incorrect.

ANSWER: B

Rationale:

The GABA-A receptor — a ligand-gated chloride channel activated by the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) — is the best-established and primary molecular target through which volatile halogenated anesthetics produce unconsciousness at clinical concentrations. All volatile halogenated agents enhance GABA-A receptor activity, increasing chloride conductance, hyperpolarizing postsynaptic neurons, and suppressing neuronal excitability in cortical, thalamic, and brainstem circuits that constitute the arousal network. Glycine receptors, another class of inhibitory ligand-gated chloride channel prominent in brainstem and spinal cord, are similarly potentiated. These receptor-level effects translate to circuit-level disruption of thalamocortical connectivity and suppression of the ascending reticular activating system, producing the dose-dependent continuum from sedation through unconsciousness and electrocerebral silence observed clinically. Option A: NMDA receptor inhibition is a mechanism shared by some anesthetics — most prominently nitrous oxide and ketamine — and volatile agents produce some degree of NMDA inhibition, but this is not the primary or dominant mechanism of unconsciousness for volatile halogenated agents at clinical concentrations. GABA-A potentiation is the more important and better-established mechanism for this agent class, making this option incorrect. Option B: Correct. GABA-A receptor potentiation is the primary molecular mechanism of volatile halogenated anesthetic-induced unconsciousness, with all volatile agents enhancing chloride conductance through this channel at clinical concentrations. Option C: K2P channels, particularly TASK-1 and TASK-3, are activated by volatile anesthetics and contribute additional hyperpolarizing current, but they are considered a contributing mechanism rather than the primary target. GABA-A receptor potentiation remains the dominant mechanism, making this option incorrect as the primary target. Option D: Volatile anesthetics do have some effect on voltage-gated sodium channels, but this is not their primary mechanism of producing unconsciousness. Sodium channel blockade is the mechanism of local anesthetics such as lidocaine and bupivacaine; attributing this as the primary mechanism of volatile agents is a category error, making this option incorrect. Option E: Nicotinic acetylcholine receptors at central synapses are not the primary targets of volatile halogenated anesthetics. While volatile agents do interact with various neurotransmitter receptor systems, GABA-A potentiation is the dominant mechanism. Nicotinic receptor blockade at the neuromuscular junction (NMJ) is the mechanism of neuromuscular blocking agents, not volatile anesthetics, making this option incorrect.

ANSWER: C

Rationale:

Enflurane is unique among the clinically used volatile anesthetics in possessing significant epileptogenic potential. At high inspired concentrations (greater than approximately 2 MAC) or in the presence of hypocapnia — which independently lowers the seizure threshold — enflurane produces characteristic EEG changes consisting of high-amplitude spike-and-wave complexes that can progress to generalized tonic-clonic seizure activity intraoperatively. This property is dose-dependent and concentration-related; at standard clinical doses with normocapnia, clinically significant seizures are uncommon. Nevertheless, enflurane is formally contraindicated in patients with known seizure disorders, and its use in neurosurgical procedures requiring cortical mapping or in patients with epilepsy is inadvisable. This epileptogenic profile is a primary reason enflurane has been displaced by isoflurane and sevoflurane, neither of which shares this property in a clinically significant way. Option A: Halothane does not activate NMDA receptors and does not have recognized epileptogenic potential. Its primary CNS effects are dose-dependent EEG slowing and cerebral vasodilation; it is not contraindicated in patients with epilepsy on the basis of seizure risk, making this option incorrect. Option B: Isoflurane does not produce clinically significant epileptogenic activity and is not contraindicated in seizure disorders. At high doses (1.5 to 2 MAC), isoflurane produces burst suppression — a deeply depressed EEG pattern that is actually used therapeutically in refractory status epilepticus — which is the opposite of pro-convulsant activity, making this option incorrect. Option C: Correct. Enflurane is the only volatile anesthetic with clinically significant epileptogenic potential, producing spike-and-wave EEG activity and seizures at high concentrations or with hypocapnia, and it is contraindicated in patients with known seizure disorders. Option D: Sevoflurane does not reliably produce seizures at standard clinical concentrations. There are isolated reports of EEG spike activity with sevoflurane, and it should be used with caution in patients with seizure disorders, but it is not contraindicated in the categorical way enflurane is, and it does not have the highest seizure rate of any volatile agent. This option overstates the risk significantly, making it incorrect. Option E: Desflurane is not associated with epileptogenic activity. Its rapid concentration changes during maintenance can trigger sympathetic activation (tachycardia and hypertension), but this is a cardiovascular effect, not a seizure mechanism, and desflurane is not contraindicated in patients with epilepsy, making this option incorrect.

ANSWER: E

Rationale:

Nitrous oxide is highly diffusible and equilibrates into air-filled body spaces far more rapidly than nitrogen (which it displaces) diffuses out — at a rate approximately 34 times faster than nitrogen. When nitrous oxide is administered in the presence of a closed air-filled space such as a pneumothorax, it rapidly diffuses into the space, increasing its volume significantly, while the nitrogen already present diffuses out much more slowly. The result is progressive expansion of the pneumothorax during the period of nitrous oxide administration, potentially converting a small simple pneumothorax to a tension pneumothorax with mediastinal shift, hemodynamic compromise, and respiratory failure. This is a direct, physically predictable consequence of nitrous oxide's diffusibility and is the basis for its contraindication not only in pneumothorax but also in bowel obstruction, pneumocephalus (air in the cranial vault), middle ear surgery, and in patients who have had vitreoretinal surgery with intraocular gas tamponade. Option A: Nitrous oxide's sympathomimetic effects on heart rate and blood pressure are mild and would not cause tension pneumothorax through an intrathoracic pressure mechanism. The relevant mechanism is physical diffusion into the air-filled space, not cardiovascular stimulation, making this option incorrect. Option B: Methionine synthase inhibition by nitrous oxide is a real toxicity relevant to prolonged or repeated exposures, but it would not impair acute pleural healing in a clinically meaningful way during a single procedure. More critically, this is not the reason nitrous oxide is contraindicated with pneumothorax; the contraindication is based on volume expansion, making this option incorrect. Option C: While reducing inspired oxygen concentration is a legitimate consideration when using high concentrations of nitrous oxide, the contraindication with pneumothorax is not about FiO₂ reduction. A patient can receive nitrous oxide at moderate concentrations without compromising oxygenation if supplemental oxygen is co-administered. The specific contraindication with air-filled spaces is diffusional expansion, making this option incorrect. Option D: Nitrous oxide does not cause clinically significant pulmonary vasoconstriction, and the mechanism described — hemodynamic conversion of pneumothorax — is not pharmacologically supported. The contraindication is based on volume expansion through diffusion, not on pulmonary vascular effects, making this option incorrect. Option E: Correct. Nitrous oxide diffuses into air-filled spaces approximately 34 times faster than nitrogen exits, causing the pneumothorax to expand and potentially converting it to a life-threatening tension pneumothorax, which is the mechanistic basis for its contraindication in this setting.

ANSWER: B

Rationale:

Among the volatile inhalational anesthetics, halothane has by far the highest fraction of absorbed dose undergoing hepatic metabolism — approximately 20% via CYP2E1. This is dramatically higher than all other agents: sevoflurane metabolizes approximately 3 to 5%, enflurane approximately 2 to 5%, isoflurane approximately 0.2%, and desflurane less than 0.02%. The clinical consequence of halothane's extensive metabolism is direct: CYP2E1-mediated oxidative metabolism generates trifluoroacetyl chloride, a reactive intermediate that covalently binds to hepatic microsomal proteins through a process called trifluoroacetylation. These trifluoroacetylated protein adducts can be recognized as neoantigens by the immune system, triggering an immune-mediated hepatitis — halothane hepatitis Type II — that presents as fulminant hepatic failure with a mortality rate of approximately 50% when it occurs. The risk is dramatically increased on re-exposure. This hepatotoxicity profile is the principal reason halothane has been replaced by modern agents in high-resource settings. Option A: Sevoflurane's hepatic metabolism is approximately 3 to 5%, which is not the highest. Compound A is formed through sevoflurane degradation by CO₂ absorbents (not hepatic metabolism) and poses a theoretical nephrotoxic rather than hepatotoxic risk in clinical use. This option misidentifies the agent with the highest metabolism and mischaracterizes the mechanism, making it incorrect. Option B: Correct. Halothane's approximately 20% hepatic metabolism via CYP2E1 is the highest of any volatile agent, generating trifluoroacetylated protein adducts that drive immune-mediated hepatotoxicity, particularly on re-exposure. Option C: Isoflurane's hepatic metabolism is only approximately 0.2%, not the highest. The statement about fluoride generation is also inaccurate — the total fluoride burden from isoflurane at clinical doses is low and not clinically significant, making this option incorrect. Option D: Desflurane's metabolism is less than 0.02%, the lowest of any volatile agent, not the highest. Describing desflurane as having an elevated hepatotoxicity profile is incorrect; its near-zero metabolism is the basis for its freedom from hepatic and renal metabolite concerns, making this option incorrect. Option E: Enflurane's metabolism is approximately 2 to 5%, which is not the highest. Additionally, enflurane does not cause clinically significant fluoride nephrotoxicity in all patients — the fluoride levels generated are lower than those from methoxyflurane, and clinical nephrotoxicity with enflurane is a concern primarily after prolonged administration in susceptible patients, not universally, making this option incorrect.

ANSWER: D

Rationale:

Isoflurane is a coronary vasodilator, and a theoretical concern about coronary steal syndrome was raised in the 1980s: the hypothesis proposed that isoflurane-induced dilation of patent coronary vessels could divert blood away from collateral-dependent territories supplied by fixed stenotic vessels that cannot vasodilate further, reducing perfusion to vulnerable myocardium. This concern prompted substantial clinical investigation. Multiple subsequent trials in patients undergoing coronary artery bypass grafting, including direct comparison studies between isoflurane and other agents, failed to demonstrate a meaningful increase in myocardial ischemia or adverse cardiac outcomes attributable to isoflurane at clinical doses of 1 MAC or less. The current consensus is that isoflurane at these concentrations does not produce clinically significant coronary steal in the vast majority of patients with CAD. It remains widely used in cardiac anesthesia. Reasonable caution is appropriate in patients with documented collateral-dependent myocardium or known steal-prone anatomy, but isoflurane is not categorically contraindicated in coronary artery disease. Option A: Isoflurane is not absolutely contraindicated in multivessel CAD and does not cause perioperative myocardial infarction in the majority of susceptible patients. This statement significantly overstates the clinical risk that the available evidence does not support, making it incorrect. Option B: No pharmacological mechanism links halothane's catecholamine sensitization to an amplification of isoflurane's coronary vasodilatory effect. These agents have distinct mechanisms and are not typically combined. This option describes a non-existent interaction, making it incorrect. Option C: Multiple large clinical trials in cardiac surgery did not confirm a statistically significant increase in perioperative myocardial infarction with isoflurane; the clinical evidence base led to the opposite conclusion — that isoflurane is safe at 1 MAC in the vast majority of patients with CAD. This option misrepresents the evidence, making it incorrect. Option D: Correct. Current consensus based on multiple clinical trials is that isoflurane at approximately 1 MAC does not produce clinically significant coronary steal in most patients with CAD, and it is not contraindicated as a class in patients with coronary artery disease. Option E: Describing the steal concern as completely disproved and isoflurane as definitively cardioprotective overstates the current evidence in the opposite direction. The consensus is that steal has not been clinically demonstrated at standard doses, but this does not translate to established cardioprotection, and reasonable caution remains appropriate in specific high-risk anatomies, making this option incorrect.

ANSWER: A

Rationale:

Compound A (fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether) is a vinyl ether produced by the degradation of sevoflurane when it contacts carbon dioxide absorbents — primarily soda lime and baralyme — within the anesthetic circuit. This degradation occurs preferentially at low fresh gas flow rates because low flow increases the residence time of sevoflurane in the absorbent canister and the temperature of the absorbent, both of which favor compound A generation. In rat models, compound A causes dose-dependent nephrotoxicity, raising concern about its potential toxicity in humans. However, multiple clinical studies in patients anesthetized with sevoflurane at low flow rates have failed to demonstrate clinically significant renal dysfunction attributable to compound A, and regulatory agencies in most countries permit its use at low flows. Some jurisdictions recommend maintaining fresh gas flows of at least 2 L/min with sevoflurane as a precautionary measure, and caution is appropriate in patients with pre-existing renal impairment undergoing prolonged procedures. Option A: Correct. Compound A is a vinyl ether formed from sevoflurane-CO₂ absorbent interaction at low flows, causes nephrotoxicity in rats, but has not been shown to cause clinically significant renal dysfunction in humans at standard use. Option B: Inorganic fluoride is generated by hepatic CYP2E1 metabolism of sevoflurane — a distinct pathway from compound A formation. Compound A is not an inorganic fluoride ion; it is a structurally specific vinyl ether. This option conflates two separate chemical entities, making it incorrect. Option C: Trifluoroacetylated protein adducts are the mechanism of halothane-associated immune hepatitis, formed by halothane's oxidative metabolite trifluoroacetyl chloride. Sevoflurane's metabolism does not produce clinically significant trifluoroacetylation, and compound A is not a trifluoroacetylated protein, making this option incorrect. Option D: Compound A is formed through absorbent interaction within the breathing circuit, not through vaporizer heating. Sevoflurane does require a heated pressurized vaporizer for delivery, but this is unrelated to compound A formation. The claim that high fresh gas flows increase compound A is also the reverse of the correct relationship; low flows increase compound A, making this option incorrect. Option E: Compound A is not a reactive oxygen species and is not generated by renal tubular metabolism of sevoflurane at standard doses. The mechanism of compound A formation is CO₂ absorbent degradation of sevoflurane in the breathing circuit, not intra-renal metabolism, and the described relationship with ventilation pattern is not pharmacologically supported, making this option incorrect.

ANSWER: C

Rationale:

Nitrous oxide irreversibly oxidizes the cobalt ion at the center of the vitamin B₁₂ molecule (cobalamin), converting it from its active reduced form (Co⁺) to an inactive oxidized form (Co³⁺). This inactivation directly inhibits methionine synthase, the enzyme that requires vitamin B₁₂ as a cofactor for conversion of homocysteine to methionine and for tetrahydrofolate regeneration needed for thymidylate synthesis. Impairment of these pathways disrupts DNA synthesis in rapidly dividing cells, with the most clinically significant consequences appearing in hematopoietic precursors and neural tissue. A single prolonged exposure to nitrous oxide can transiently impair DNA synthesis; repeated or prolonged exposures — as seen historically in occupational exposure before scavenging systems, or in patients receiving repeated nitrous oxide anesthetics for burn dressing changes — can cause megaloblastic anemia and subacute combined degeneration of the spinal cord (a posterior and lateral column myelopathy). In patients who are already vitamin B₁₂ deficient, even a single exposure may precipitate or worsen these complications because the available reserve is already depleted. Option A: Nitrous oxide does not compete with vitamin B₁₂ at ileal absorption receptors. Vitamin B₁₂ absorption from the ileum requires intrinsic factor and specific mucosal receptors, and nitrous oxide interacts with B₁₂ directly at the molecular level through oxidation of the cobalt ion, not at the site of absorption, making this option incorrect. Option B: Nitrous oxide does not displace B₁₂ from plasma carrier proteins or accelerate renal excretion. The mechanism of B₁₂ inactivation is direct irreversible oxidation of the cobalt ion within the B₁₂ molecule itself, making this option incorrect. Option C: Correct. Nitrous oxide irreversibly oxidizes the cobalt ion of vitamin B₁₂, inactivating methionine synthase, impairing DNA synthesis, and producing megaloblastic anemia and subacute combined degeneration with prolonged or repeated exposure, with heightened risk in patients with pre-existing B₁₂ deficiency. Option D: Propionyl-CoA carboxylase is not a vitamin B₁₂-dependent enzyme; it is biotin-dependent. The B₁₂-dependent enzyme in propionate metabolism is methylmalonyl-CoA mutase, and its involvement in nitrous oxide toxicity is indirect through B₁₂ inactivation rather than direct competitive inhibition. This option contains a factual error in enzyme biochemistry and mischaracterizes the mechanism, making it incorrect. Option E: Nitrous oxide is not metabolized by CYP2E1 and does not induce CYP2E1-mediated metabolism of vitamin B₁₂ in hepatocytes. The interaction is a direct chemical oxidation of the B₁₂ cobalt ion by nitrous oxide, not a hepatic metabolic interaction, making this option incorrect.

ANSWER: B

Rationale:

A unique and clinically important property of desflurane is its tendency to produce transient but marked sympathetic activation — manifesting as tachycardia and hypertension — when inspired concentration is increased rapidly. The mechanism involves stimulation of pulmonary irritant receptors by desflurane at concentrations above approximately 1 MAC delivered via rapid ramp-up, triggering a reflex increase in sympathetic outflow. This response is most prominent when desflurane concentration is increased quickly, as in the scenario described, and is not seen to the same degree when concentration is increased gradually. The practical clinical consequence is that desflurane concentration should be increased slowly and incrementally, particularly in patients with coronary artery disease or hypertension, in whom this transient sympathetic surge could provoke myocardial ischemia or dangerous arrhythmias. This property of rapid-ramp sympathetic activation is specific to desflurane among the volatile agents and does not occur with sevoflurane, isoflurane, or halothane to a clinically meaningful degree at equivalent ramp speeds. Option A: Desflurane does not directly stimulate myocardial beta-1 adrenergic receptors. The tachycardia and hypertension arise from reflex sympathetic activation secondary to pulmonary irritant receptor stimulation, not direct cardiac receptor agonism. No volatile anesthetic has a recognized mechanism of direct myocardial adrenergic receptor stimulation, making this option incorrect. Option B: Correct. Rapid increases in desflurane concentration stimulate pulmonary irritant receptors, producing reflex sympathetic activation with tachycardia and hypertension, and this response is the basis for the recommendation to increase desflurane concentration gradually, particularly in high-risk patients. Option C: While desflurane does reduce systemic vascular resistance at stable maintenance concentrations, the baroreceptor-mediated reflex tachycardia from vasodilation is a gradual hemodynamic adjustment, not the abrupt and dramatic sympathetic surge described in the scenario. The mechanism of the rapid hemodynamic response to concentration increase is pulmonary irritant receptor stimulation, not vasodilation-mediated baroreceptor reflex, making this option incorrect. Option D: Desflurane does not directly stimulate adrenomedullary nicotinic receptors to cause epinephrine release. The sympathetic activation is a reflex neural response mediated through pulmonary irritant receptors and the sympathetic nervous system, not direct adrenomedullary stimulation by the desflurane molecule, making this option incorrect. Option E: Malignant hyperthermia (MH) is triggered by halogenated volatile agents, including desflurane, but MH presents with hyperthermia, rigidity, masseter spasm, combined metabolic and respiratory acidosis, and hyperkalemia — not with isolated tachycardia and hypertension immediately following a concentration increase. The scenario describes a predictable pharmacological response to rapid desflurane ramp-up, not MH, and administering dantrolene would be inappropriate and potentially harmful in this context, making this option incorrect.

ANSWER: E

Rationale:

Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle calcium regulation, most commonly linked to mutations in the RyR1 gene encoding the ryanodine receptor type 1 channel on the sarcoplasmic reticulum. In susceptible individuals, triggering agents cause uncontrolled release of calcium from the sarcoplasmic reticulum, producing skeletal muscle hypermetabolism with hyperthermia, rigidity, combined metabolic and respiratory acidosis, and hyperkalemia. All volatile halogenated agents — halothane, isoflurane, sevoflurane, desflurane, and enflurane — are established MH triggers in susceptible patients. Nitrous oxide, which is not a halogenated compound and lacks the structural features responsible for RyR1 activation, is not an MH trigger and does not cause MH in susceptible patients. Succinylcholine is the only non-volatile triggering agent. Nitrous oxide may therefore be used as part of an anesthetic plan for MH-susceptible patients, provided that all halogenated volatile agents are avoided and the anesthetic machine has been appropriately purged. Option A: Nitrous oxide is not a volatile halogenated agent and does not share the structural properties that allow halogenated agents to activate RyR1. The claim that it is a potent MH trigger through membrane lipid interactions is pharmacologically incorrect, making this option incorrect. Option B: Nitrous oxide is not a moderate or concentration-dependent MH trigger. There is no dose below which a true halogenated trigger becomes safe and no dose above which nitrous oxide becomes unsafe with respect to MH. This option incorrectly implies a dose-dependent triggering relationship that does not exist for nitrous oxide, making it incorrect. Option C: The MH risk associated with volatile halogenated agents applies regardless of whether the RyR1 mutation is homozygous or heterozygous; MH susceptibility is an autosomal dominant condition where a single mutant allele confers susceptibility. Nitrous oxide does not trigger MH in either genotype, and genotyping is not required to safely administer nitrous oxide to MH-susceptible patients, making this option incorrect. Option D: Succinylcholine is indeed a non-volatile MH trigger, but nitrous oxide does not become an MH trigger when combined with succinylcholine. The two agents have entirely distinct mechanisms of action and their combination does not create an MH-triggering interaction for nitrous oxide, making this option incorrect. Option E: Correct. All volatile halogenated agents are MH triggers. Nitrous oxide, lacking halogenation and the structural features that activate RyR1, is not an MH trigger and may be used safely in MH-susceptible patients as part of a TIVA-based or non-halogenated anesthetic plan.

ANSWER: D

Rationale:

Sevoflurane emergence agitation — also called emergence delirium — is a well-characterized adverse effect of sevoflurane anesthesia, particularly in young children. It occurs in approximately 20 to 80% of children in various reports and presents as inconsolable crying, thrashing, disorientation, and failure to recognize caregivers, beginning within minutes of awakening and typically resolving within 15 to 30 minutes. The scenario described — a preschool-aged child with a history of multiple similar episodes following sevoflurane — is a classic presentation. The mechanism is thought to relate to the rapid offset of sevoflurane sedation producing a dysphoric transitional state before full cortical reintegration, compounded by pain, anxiety, and the ENT surgical context. Preventive strategies with established efficacy include midazolam premedication, a smoothing dose of propofol (1 mg/kg IV) at the end of the procedure, fentanyl 1 to 2 mcg/kg before emergence, adequate multimodal analgesia, and dexmedetomidine (0.3 to 0.5 mcg/kg IV) administered near procedure end. This phenomenon is distinct from postoperative delirium in adults. Option A: Postoperative delirium is a distinct and more prolonged syndrome affecting elderly patients through neuroinflammatory mechanisms; it is not the same as pediatric emergence agitation, which is self-limited and resolves within 15 to 30 minutes. Requiring exclusively TIVA for all future procedures would be an excessive and unsupported intervention for emergence agitation, making this option incorrect. Option B: Opioid-induced dysphoria is a recognized entity but presents differently from emergence agitation and would be expected to occur in the context of documented opioid excess. Normal vital signs with stable oxygen saturation do not suggest opioid toxicity, and the history of three identical episodes following sevoflurane strongly supports the diagnosis of emergence agitation. Recommending naloxone and eliminating all opioids in pediatric tonsillectomy is not supported by evidence and would increase pain, making this option incorrect. Option C: Laryngospasm produces stridor, oxygen desaturation, and accessory muscle use — none of which are present here. Oxygen saturation is 99% on room air, making hypoxia-driven agitation pharmacologically and clinically inconsistent with the presentation, and the pattern of three recurrent episodes with sevoflurane further supports emergence agitation as the correct diagnosis, making this option incorrect. Option D: Correct. The presentation is consistent with sevoflurane emergence agitation, and midazolam premedication, end-of-case propofol, adequate analgesia, and dexmedetomidine are all evidence-based preventive strategies. Option E: Paradoxical reactions to midazolam can occur in children but are not characterized by the recurrent, post-sevoflurane-specific pattern described, nor do they present as a syndrome recognized across three consecutive anesthetics. The mechanism described — reversal of GABA-A sedation during emergence — does not accurately characterize how paradoxical midazolam reactions occur, and ketamine substitution is not a guideline-supported prevention strategy for emergence agitation, making this option incorrect.

ANSWER: A

Rationale:

Isoflurane reduces cerebral metabolic rate for oxygen (CMRO₂) in a dose-dependent and concentration-dependent manner. At doses of approximately 1.5 to 2 MAC, isoflurane produces an isoelectric or burst-suppression EEG pattern — a state of alternating bursts of electrical activity and periods of complete electrocerebral silence that reflects near-maximal metabolic depression achievable with this agent. This property has been exploited in neurosurgical procedures requiring temporary arterial occlusion (such as temporary clipping during aneurysm surgery or as in this scenario) to reduce cerebral metabolic demand during the ischemic interval, theoretically extending the tolerable duration of ischemia. Compared to halothane, isoflurane produces this degree of EEG suppression with less cardiovascular depression at equivalent anesthetic depth, and its cerebrovascular effects — while present — are less pronounced than halothane's, giving it a more favorable neurosurgical profile. Option A: Correct. Isoflurane at approximately 1.5 to 2 MAC produces burst suppression through dose-dependent CMRO₂ reduction, and this property is used for cerebral protection during temporary vessel occlusion in neurosurgery. Option B: Burst suppression with isoflurane is not achieved at 0.5 MAC; that concentration represents a very light to moderate plane of anesthesia. The burst-suppression range is approximately 1.5 to 2 MAC, and the mechanism involves CMRO₂ reduction, not selective voltage-gated potassium channel activation independent of metabolic effects, making this option incorrect. Option C: EEG burst suppression produced by isoflurane is a global phenomenon reflecting widespread CMRO₂ reduction across the entire brain, not focal suppression of a specific territory. Volatile anesthetic effects are systemic, and the EEG changes reflect global rather than regional brain depression, making this option incorrect. Option D: Burst suppression occurs at approximately 1.5 to 2 MAC, not 0.3 MAC. At 0.3 MAC isoflurane produces mild sedation. The described mechanism of selective reticular activating system inhibition with spared cortical metabolism is pharmacologically incorrect — burst suppression reflects global CMRO₂ reduction, not selective subcortical inhibition, making this option incorrect. Option E: Propofol can produce pharmacological burst suppression and is used for this purpose, but isoflurane is also well established as an agent capable of achieving burst suppression at approximately 1.5 to 2 MAC without causing hemodynamic collapse. The claim that volatile agents cannot achieve burst suppression concentrations is factually incorrect, making this option incorrect.

ANSWER: C

Rationale:

The Meyer-Overton correlation is an empirical observation, established independently by Meyer and Overton around 1900, that anesthetic potency (as reflected by MAC) correlates strongly with lipid solubility, expressed as the oil:gas partition coefficient. Agents with high oil:gas partition coefficients are more lipid-soluble and penetrate lipid-rich neural membranes more readily, requiring lower alveolar concentrations to achieve anesthesia — hence a lower MAC. Halothane has an oil:gas coefficient of approximately 224, reflecting very high lipid solubility, and its MAC is approximately 0.75% — a high-potency agent requiring a small inspired fraction. Desflurane has an oil:gas coefficient of only approximately 19, reflecting much lower lipid solubility, and its MAC is approximately 6 to 7% — far less potent on a percentage basis. This inverse relationship between oil:gas coefficient and MAC holds across the volatile anesthetic agents and provides a mechanistic rationale linking lipid solubility to anesthetic potency, now understood to reflect modulation of lipid-embedded ion channel proteins rather than bulk membrane fluidization. Option A: Molecular size and steric bulk are not established determinants of MAC. The Meyer-Overton correlation focuses on lipid solubility (oil:gas partition coefficient), not molecular volume or steric properties. This option proposes a mechanism unsupported by pharmacological evidence, making it incorrect. Option B: Anesthetic metabolites of halothane do not have significant anesthetic activity, and the active anesthetic effect is produced by the parent molecule at the brain. MAC reflects the alveolar partial pressure of the parent agent, not metabolite contribution. Attributing halothane's lower MAC to its higher metabolism misrepresents the mechanism of anesthetic potency, making this option incorrect. Option C: Correct. The Meyer-Overton correlation links anesthetic potency to lipid solubility expressed as the oil:gas partition coefficient; halothane's oil:gas coefficient of approximately 224 is far greater than desflurane's approximately 19, accounting for halothane's much lower MAC. Option D: The blood:gas partition coefficient determines the rate of induction (speed of equilibration), not potency. A high blood:gas coefficient means more agent must dissolve in blood before alveolar partial pressure rises, producing a slower induction, but it does not determine the concentration at which anesthesia is produced. The oil:gas coefficient determines potency; confusing these two partition coefficients is a common error, making this option incorrect. Option E: The specific identity of halogen substituents (fluorine, chlorine, bromine) does not directly determine MAC through differential GABA-A potency in the way described. The Meyer-Overton correlation, based on bulk lipid solubility, provides the accepted explanation for MAC differences across volatile agents; a halogen-counting model of receptor activation is not supported by current pharmacological evidence, making this option incorrect.

ANSWER: B

Rationale:

Halothane's cardiovascular profile is characterized by direct myocardial depression resulting from impaired intracellular calcium handling — specifically, inhibition of calcium entry into cardiomyocytes and disruption of calcium release from the sarcoplasmic reticulum. This produces dose-dependent reductions in cardiac output, contractility, and heart rate. The critical distinguishing feature between halothane and modern volatile agents such as isoflurane and desflurane is that isoflurane's hypotension is primarily driven by peripheral vasodilation, which reflexively stimulates baroreceptors to increase sympathetic outflow and heart rate — so cardiac output is relatively maintained. Halothane, by contrast, produces comparatively modest vasodilation; its hypotension is predominantly due to myocardial depression, and without the baroreceptor trigger of significant vasodilation, the heart rate does not rise. The result is the pattern seen here: bradycardia with falling blood pressure, representing depressed cardiac function without a compensatory increase in rate, in contrast to the tachycardic, vasodilated pattern of isoflurane. Option A: Halothane does not block beta-1 or alpha-1 adrenergic receptors. Its cardiovascular effects arise from direct impairment of myocardial calcium handling, not from receptor blockade. Attributing the bradycardia to adrenergic receptor antagonism is a mechanistic error, making this option incorrect. Option B: Correct. Halothane's direct myocardial depression reduces heart rate and cardiac output through impaired calcium handling; the absence of significant peripheral vasodilation means baroreceptors are not triggered to produce reflex tachycardia, resulting in the characteristic bradycardia seen clinically. Option C: Halothane does not directly activate muscarinic M2 receptors. Its bradycardia arises from direct depression of the sinoatrial node through impaired calcium handling, not through parasympathomimetic agonism. Attributing unresponsiveness to atropine is also pharmacologically unfounded, making this option incorrect. Option D: Halothane does not stimulate alpha-1 adrenergic receptors and does not produce systemic hypertension; it causes modest vasodilation and myocardial depression, both of which reduce blood pressure. The premise of this option is the opposite of halothane's actual pharmacology, making it incorrect. Option E: Halothane does not produce reflex tachycardia through selective vascular L-type calcium channel blockade; this description incorrectly characterizes halothane's pharmacology and would describe an agent more similar to a dihydropyridine calcium channel blocker. The bradycardia in this scenario is a predictable, well-characterized pharmacological effect of halothane, not an idiosyncratic reaction, making this option incorrect.

ANSWER: E

Rationale:

Nitrous oxide increases the incidence of PONV through mechanisms that include stimulation of the chemoreceptor trigger zone via dopaminergic and opioid pathways, as well as direct gastrointestinal effects. Critically, this PONV risk is duration-dependent: the risk ratio for PONV with versus without nitrous oxide rises with increasing procedure length, and the number needed to treat to prevent one PONV case by avoiding nitrous oxide falls from more than 100 for procedures under one hour to approximately 9 for procedures exceeding two hours. The patient in this scenario has a procedure of 2.5 hours — solidly in the range where nitrous oxide makes a meaningful PONV contribution — and an Apfel score of 4, indicating maximum baseline PONV risk. In such patients, nitrous oxide avoidance is a recognized component of multimodal PONV prevention strategy alongside total intravenous anesthesia with propofol (which has antiemetic properties), multimodal antiemetic prophylaxis (5-HT3 antagonists, dexamethasone, and scopolamine patch), and opioid minimization. Omitting nitrous oxide is a zero-cost intervention in high-risk patients and is supported by clinical evidence. Option A: Nitrous oxide does not reduce PONV risk. Its sympathomimetic cardiovascular effects do not translate to beneficial gastric or lower esophageal sphincter effects, and it is associated with increased, not decreased, PONV incidence, making this option incorrect. Option B: The PONV contribution of nitrous oxide is not negligible for procedures under 3 hours; the evidence shows the number needed to harm falls to approximately 9 for procedures exceeding 2 hours. This patient's 2.5-hour procedure is already in the risk range where nitrous oxide avoidance is clinically meaningful. The threshold cited in this option is incorrect, making it incorrect. Option C: The primary mechanism through which nitrous oxide contributes to PONV involves dopaminergic and opioid pathways in the chemoreceptor trigger zone, not 5-HT3 receptor inhibition. Additionally, 5-HT3 antagonists such as ondansetron remain effective antiemetics in patients receiving nitrous oxide and are not rendered ineffective, making this option pharmacologically incorrect. Option D: Nitrous oxide can expand bowel gas in the context of bowel obstruction, but the PONV contribution of nitrous oxide in laparoscopic procedures is primarily through chemoreceptor trigger zone mechanisms, not through doubling of PONV incidence via bowel distension. The statement that nitrous oxide doubles laparoscopic PONV incidence regardless of duration is not supported by evidence, making this option incorrect. Option E: Correct. Nitrous oxide's PONV contribution is duration-dependent, and in this high-Apfel-score patient undergoing a 2.5-hour procedure, nitrous oxide avoidance is a component of evidence-based multimodal PONV prevention.

ANSWER: A

Rationale:

The blood:gas partition coefficient is the fundamental determinant of induction speed for inhalational anesthetics. A higher coefficient means greater blood solubility, requiring more agent to dissolve in blood before the alveolar partial pressure rises to anesthetic levels — producing a slower induction. Enflurane has a blood:gas partition coefficient of approximately 1.9, placing it in the higher-solubility range alongside halothane (2.4) and well above the modern agents sevoflurane (0.65) and desflurane (0.42). This difference in blood solubility directly accounts for enflurane's slower induction compared to these newer agents. The rank order of induction speed from fastest to slowest across the volatile agents directly mirrors the inverse rank of blood:gas coefficients: desflurane ≈ nitrous oxide > sevoflurane > isoflurane > enflurane > halothane. Understanding this relationship allows the clinician to predict induction and emergence behavior for any agent from a single pharmacokinetic parameter. Option A: Correct. Enflurane's blood:gas coefficient of approximately 1.9 reflects higher blood solubility than sevoflurane (0.65) or desflurane (0.42), requiring greater blood dissolution before alveolar equilibration occurs and producing slower induction. Option B: Enflurane's blood:gas coefficient is approximately 1.9, not 0.42 (which is desflurane's value). The higher coefficient reflects higher blood solubility and slower equilibration — the kinetic basis for its slower induction — independent of any difference in MAC, making this option incorrect. Option C: Enflurane's blood:gas coefficient is approximately 1.9, not 2.4. A coefficient of 2.4 describes halothane, not enflurane. Furthermore, while enflurane does undergo hepatic metabolism (approximately 2 to 5%), this is not the mechanism of its slower induction; all volatile agents undergo some hepatic metabolism without it substantially altering induction kinetics. Partition coefficient is the primary determinant, making this option incorrect. Option D: Enflurane's blood:gas coefficient is approximately 1.9, not 0.65. A coefficient of 0.65 describes sevoflurane. Volatile anesthetic kinetics are determined by partition coefficients, not by plasma protein binding (which is relevant to intravenous agents), making this option incorrect. Option E: Enflurane's blood:gas coefficient is approximately 1.9, not 1.4. A coefficient of 1.4 describes isoflurane. While isoflurane and enflurane have somewhat similar coefficients and both produce moderately slow inductions, they are not identical, and the values differ sufficiently to produce clinically distinguishable kinetics. The claim that differences are due solely to vaporizer calibration rather than pharmacokinetics is incorrect, making this option incorrect.

ANSWER: D

Rationale:

Desflurane undergoes the lowest hepatic metabolism of any volatile halogenated agent, with less than 0.02% of absorbed dose metabolized via CYP2E1. This near-zero metabolism produces negligible quantities of inorganic fluoride and virtually no trifluoroacetylated protein adducts — the reactive intermediates responsible for halothane's immune-mediated hepatitis and the lower-level hepatotoxic risk associated with isoflurane and enflurane. For a patient with a history of halothane-associated hepatitis, this metabolic profile makes desflurane the volatile halogenated agent with the lowest theoretical hepatotoxicity risk. Sevoflurane (approximately 3 to 5% metabolism) and enflurane (approximately 2 to 5%) have considerably higher metabolism fractions. Isoflurane (approximately 0.2%) is also very low but still one order of magnitude higher than desflurane. The rank order from lowest to highest hepatic metabolism among volatile agents is: desflurane (<0.02%) < isoflurane (0.2%) < enflurane (2 to 5%) ≈ sevoflurane (3 to 5%) << halothane (approximately 20%). Option A: Sevoflurane's hepatic metabolism is approximately 3 to 5%, not less than 0.02%. It does generate inorganic fluoride ions (which can transiently exceed the methoxyflurane nephrotoxicity threshold, though clinical nephrotoxicity is rare). Describing it as having the lowest metabolism is factually incorrect, making this option incorrect. Option B: Isoflurane's hepatic metabolism is approximately 0.2%, not less than 0.02%. Isoflurane does have very low metabolism and a favorable hepatic safety profile, but it is not equal to desflurane in metabolic inertness — desflurane's metabolism is approximately 10-fold lower. The claim of structural similarity producing shared metabolic inertness is imprecise, making this option incorrect. Option C: While nitrous oxide undergoes essentially no mammalian hepatic metabolism, it is not a volatile halogenated agent and is typically used as an adjunct rather than a sole maintenance agent. More importantly, the question asks about volatile agents in the context of hepatotoxic metabolite risk, and the correct comparison within the volatile halogenated class is between desflurane, isoflurane, sevoflurane, enflurane, and halothane. Selecting nitrous oxide as the answer avoids the pharmacological question being asked, making this option incorrect. Option D: Correct. Desflurane has the lowest hepatic metabolism of any volatile halogenated agent at less than 0.02%, generating negligible trifluoroacetylated protein and minimal fluoride, making it the safest volatile agent with respect to hepatotoxic metabolite generation. Option E: Enflurane's hepatic metabolism is approximately 2 to 5%, not 0.2% — the 0.2% figure describes isoflurane. More critically, higher molecular weight does not protect against trifluoroacetylated protein generation in the way described; trifluoroacetylation occurs based on CYP2E1-mediated production of the reactive trifluoroacetyl chloride intermediate, and the absolute risk depends on the mass of metabolite generated. Enflurane is not the lowest-metabolism agent, making this option incorrect.

ANSWER: C

Rationale:

Sevoflurane is the preferred volatile agent for patients with asthma or reactive airways disease in high-resource settings. It is a clinically significant bronchodilator — relaxing bronchial smooth muscle through mechanisms that include inhibition of airway smooth muscle calcium signaling and modulation of cholinergic tone — and its non-pungent, somewhat sweet odor means it does not irritate the airways during induction or maintenance, even at concentrations required for inhalational induction. These properties make it both a safe induction agent and a bronchodilatory maintenance agent for the asthmatic patient. Sevoflurane has largely replaced halothane for this indication in settings where it is available, given halothane's cardiovascular disadvantages (myocardial depression, catecholamine sensitization) despite halothane's also being a potent bronchodilator. In contrast, desflurane is a significant airway irritant and is actively avoided in patients with reactive airways, particularly during induction. Isoflurane has bronchodilatory properties but has a more pungent odor than sevoflurane and is not suitable for inhalational induction. Option A: Desflurane is specifically avoided in patients with reactive airways because it is a significant airway irritant, frequently causing bronchospasm. Using it in an asthmatic patient and relying on rapid titration to respond to bronchospasm inverts the correct clinical approach; the goal is to prevent bronchospasm, not to respond rapidly after it occurs. Desflurane is the wrong choice for this patient, making this option incorrect. Option B: Isoflurane has bronchodilatory properties and is used in patients with reactive airways, but it is not superior to sevoflurane as a bronchodilator and has a more pungent odor that can irritate airways during induction — a relevant limitation for patients with bronchospasm risk. Sevoflurane remains the preferred agent in high-resource settings, not isoflurane. The claim that isoflurane produces no airway irritation at any concentration is also inaccurate, making this option incorrect. Option C: Correct. Sevoflurane is a bronchodilator with no airway irritant properties, is suitable for inhalational induction, and is the preferred volatile agent for patients with reactive airways disease in high-resource settings, having largely replaced halothane for this indication. Option D: Nitrous oxide has minimal direct effect on airway smooth muscle tone, but selecting it as the preferred agent for asthma management through a MAC-sparing mechanism is not pharmacologically sound practice. The agent providing active bronchodilation — sevoflurane — is the appropriate primary volatile agent; nitrous oxide does not substitute for bronchodilatory volatile agent selection, making this option incorrect. Option E: Isoflurane is not contraindicated in asthma and is not a bronchoconstrictor. It is a bronchodilator, as are all commonly used volatile agents. The described mechanism — sympathetically mediated paradoxical bronchoconstriction through beta-2 receptor activation — is pharmacologically unfounded and describes the opposite of isoflurane's actual airway effects, making this option incorrect.